Having trouble accessing articles? Reset your cache.

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

Jazz gains essential tremor asset via Cavion takeout
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) acquired Cavion Inc. for $52.5 million up front and up to $260 million in clinical, regulatory

Read the full 284 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE